Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears

Gila Lithwick-Yanai, Nir Dromi, Alexander Shtabsky, Sara Morgenstern, Yulia Strenov, Meora Feinmesser, Vladimir Kravtsov, Marino E. Leon, Marián Hajdúch, Syed Z Ali, Christopher VandenBussche, Xinmin Zhang, Leonor Leider-Trejo, Asia Zubkov, Sergey Vorobyov, Michal Kushnir, Yaron Goren, Sarit Tabak, Etti Kadosh, Hila BenjaminTemima Schnitzer-Perlman, Hagai Marmor, Maria Motin, Danit Lebanony, Sharon Kredo-Russo, Heather Mitchell, Melissa Noller, Alexis Smith, Olivia Dattner, Karin Ashkenazi, Mats Sanden, Kenneth A. Berlin, Dganit Bar, Eti Meiri

Research output: Contribution to journalArticle

Abstract

Aims The distinction between benign and malignant thyroid nodules has important therapeutic implications. Our objective was to develop an assay that could classify indeterminate thyroid nodules as benign or suspicious, using routinely prepared fine needle aspirate (FNA) cytology smears. Methods A training set of 375 FNA smears was used to develop the microRNA-based assay, which was validated using a blinded, multicentre, retrospective cohort of 201 smears. Final diagnosis of the validation samples was determined based on corresponding surgical specimens, reviewed by the contributing institute pathologist and two independent pathologists. Validation samples were from adult patients (≥18 years) with nodule size >0.5 cm, and a final diagnosis confirmed by at least one of the two blinded, independent pathologists. The developed assay, RosettaGX Reveal, differentiates benign from malignant thyroid nodules, using quantitative RT-PCR. Results Test performance on the 189 samples that passed quality control: negative predictive value: 91% (95% CI 84% to 96%); sensitivity: 85% (CI 74% to 93%); specificity: 72% (CI 63% to 79%). Performance for cases in which all three reviewing pathologists were in agreement regarding the final diagnosis (n=150): negative predictive value: 99% (CI 94% to 100%); sensitivity: 98% (CI 87% to 100%); specificity: 78% (CI 69% to 85%). Conclusions A novel assay utilising microRNA expression in cytology smears was developed. The assay distinguishes benign from malignant thyroid nodules using a single FNA stained smear, and does not require fresh tissue or special collection and shipment conditions. This assay offers a valuable tool for the preoperative classification of thyroid samples with indeterminate cytology.

Original languageEnglish (US)
JournalJournal of Clinical Pathology
DOIs
StateAccepted/In press - Oct 26 2016

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears'. Together they form a unique fingerprint.

  • Cite this

    Lithwick-Yanai, G., Dromi, N., Shtabsky, A., Morgenstern, S., Strenov, Y., Feinmesser, M., Kravtsov, V., Leon, M. E., Hajdúch, M., Ali, S. Z., VandenBussche, C., Zhang, X., Leider-Trejo, L., Zubkov, A., Vorobyov, S., Kushnir, M., Goren, Y., Tabak, S., Kadosh, E., ... Meiri, E. (Accepted/In press). Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2016-204089